Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

Expression profiling and intracellular localization studies of the novel Proline-, Histidine-, and Glycine-rich protein 1 suggest an essential role in gastro-intestinal epithelium and a potential clinical application in colorectal cancer diagnostics.

Oltedal S, Skaland I, Maple-Grødem J, Tjensvoll K, Janssen EAM, Gilje B, Smaaland R, Heikkilä R, Nordgård O.

BMC Gastroenterol. 2018 Feb 7;18(1):26. doi: 10.1186/s12876-018-0752-8.

2.

Low Protein A20 in Minor Salivary Glands is Associated with Lymphoma in Primary Sjögren's Syndrome.

Johnsen SJ, Gudlaugsson E, Skaland I, Janssen EA, Jonsson MV, Helgeland L, Berget E, Jonsson R, Omdal R.

Scand J Immunol. 2016 Mar;83(3):181-7. doi: 10.1111/sji.12405.

3.

Reduced Number of CD8+ Cells in Tonsillar Germinal Centres in Children with the Periodic Fever, Aphthous Stomatitis, Pharyngitis and Cervical Adenitis Syndrome.

Førsvoll J, Janssen EA, Møller I, Wathne N, Skaland I, Klos J, Kristoffersen EK, Øymar K.

Scand J Immunol. 2015 Jul;82(1):76-83. doi: 10.1111/sji.12303.

4.

Prognostic comparison of proliferation markers and World Health Organization 1973/2004 grades in urothelial carcinomas of the urinary bladder.

Mangrud OM, Gudlaugsson E, Skaland I, Tasdemir I, Dalen I, van Diermen B, Baak JP, Janssen EA.

Hum Pathol. 2014 Jul;45(7):1496-503. doi: 10.1016/j.humpath.2014.03.001. Epub 2014 Mar 26.

PMID:
24796506
5.

Prognostic value of gene signatures and proliferation in lymph-node-negative breast cancer.

Jonsdottir K, Assmus J, Slewa A, Gudlaugsson E, Skaland I, Baak JP, Janssen EA.

PLoS One. 2014 Mar 5;9(3):e90642. doi: 10.1371/journal.pone.0090642. eCollection 2014.

6.

The prognostic value of mitotic activity index (MAI), phosphohistone H3 (PPH3), cyclin B1, cyclin A, and Ki67, alone and in combinations, in node-negative premenopausal breast cancer.

Klintman M, Strand C, Ahlin C, Beglerbegovic S, Fjällskog ML, Grabau D, Gudlaugsson E, Janssen EA, Lövgren K, Skaland I, Bendahl PO, Malmström P, Baak JP, Fernö M.

PLoS One. 2013 Dec 4;8(12):e81902. doi: 10.1371/journal.pone.0081902. eCollection 2013.

7.

Can proliferation biomarkers reliably predict recurrence in World Health Organization 2003 defined endometrial stromal sarcoma, low grade?

Feng W, Malpica A, Skaland I, Gudlaugsson E, Robboy SJ, Dalen I, Hua K, Zhou X, Baak JP.

PLoS One. 2013 Oct 11;8(10):e75899. doi: 10.1371/journal.pone.0075899. eCollection 2013.

9.

Validation of expression patterns for nine miRNAs in 204 lymph-node negative breast cancers.

Jonsdottir K, Janssen SR, Da Rosa FC, Gudlaugsson E, Skaland I, Baak JP, Janssen EA.

PLoS One. 2012;7(11):e48692. doi: 10.1371/journal.pone.0048692. Epub 2012 Nov 7.

10.

Consistent condom use increases spontaneous regression in high-risk non-HPV16 but not in HPV16 CIN2-3 lesions, a prospective population-based cohort study.

Munk AC, Ovestad IT, Gudlaugsson E, Løvslett K, Fiane B, van Diermen-Hidle B, Kruse AJ, Skaland I, Janssen EA, Baak JP.

Infect Agent Cancer. 2012 Nov 5;7(1):30. doi: 10.1186/1750-9378-7-30.

11.

Interaction of epithelial biomarkers, local immune response and condom use in cervical intraepithelial neoplasia 2-3 regression.

Munk AC, Gudlaugsson E, Ovestad IT, Lovslett K, Fiane B, Hidle Bv, Kruse AJ, Skaland I, Janssen EA, Baak JP.

Gynecol Oncol. 2012 Dec;127(3):489-94. doi: 10.1016/j.ygyno.2012.09.010. Epub 2012 Sep 24.

PMID:
23017821
12.

Comparison of the effect of different techniques for measurement of Ki67 proliferation on reproducibility and prognosis prediction accuracy in breast cancer.

Gudlaugsson E, Skaland I, Janssen EA, Smaaland R, Shao Z, Malpica A, Voorhorst F, Baak JP.

Histopathology. 2012 Dec;61(6):1134-44. doi: 10.1111/j.1365-2559.2012.04329.x. Epub 2012 Sep 11.

PMID:
22963617
13.

The prognostic value of MARCKS-like 1 in lymph node-negative breast cancer.

Jonsdottir K, Zhang H, Jhagroe D, Skaland I, Slewa A, Björkblom B, Coffey ET, Gudlaugsson E, Smaaland R, Janssen EA, Baak JP.

Breast Cancer Res Treat. 2012 Sep;135(2):381-90. doi: 10.1007/s10549-012-2155-9. Epub 2012 Jul 8.

PMID:
22772381
14.

Discrimination of grade 2 and 3 cervical intraepithelial neoplasia by means of analysis of water soluble proteins recovered from cervical biopsies.

Uleberg KE, Munk AC, Brede C, Gudlaugsson E, van Diermen B, Skaland I, Malpica A, Janssen EA, Hjelle A, Baak JP.

Proteome Sci. 2011 Jun 28;9:36. doi: 10.1186/1477-5956-9-36.

15.

A protein profile study to discriminate CIN lesions from normal cervical epithelium.

Uleberg KE, Munk AC, Skaland I, Furlan C, van Diermen B, Gudlaugsson E, Janssen EA, Malpica A, Feng W, Hjelle A, Baak JP.

Cell Oncol (Dordr). 2011 Oct;34(5):443-50. doi: 10.1007/s13402-011-0047-3. Epub 2011 May 15.

16.

Biomarkers and microsatellite instability analysis of curettings can predict the behavior of FIGO stage I endometrial endometrioid adenocarcinoma.

Steinbakk A, Malpica A, Slewa A, Skaland I, Gudlaugsson E, Janssen EA, Løvslett K, Fiane B, Kruse AJ, Feng W, Yinhua Y, Baak JP.

Mod Pathol. 2011 Sep;24(9):1262-71. doi: 10.1038/modpathol.2011.75. Epub 2011 May 6.

17.

The impact of epithelial biomarkers, local immune response and human papillomavirus genotype in the regression of cervical intraepithelial neoplasia grades 2-3.

Ovestad IT, Gudlaugsson E, Skaland I, Malpica A, Munk AC, Janssen EA, Baak JP.

J Clin Pathol. 2011 Apr;64(4):303-7. doi: 10.1136/jcp.2010.083626.

PMID:
21421698
18.

The prognostic value of the orphan nuclear receptor DAX-1 (NROB1) in node-negative breast cancer.

Zhang H, Slewa A, Janssen E, Skaland I, Yu Y, Gudlaugsson E, Feng W, Kjellevold K, Søiland H, Baak JP.

Anticancer Res. 2011 Feb;31(2):443-9.

PMID:
21378322
19.

Molecular biomarkers in endometrial hyperplasias predict cancer progression.

Steinbakk A, Gudlaugsson E, Aasprong OG, Skaland I, Malpica A, Feng W, Janssen EA, Baak JP.

Am J Obstet Gynecol. 2011 Apr;204(4):357.e1-12. doi: 10.1016/j.ajog.2010.12.007. Epub 2011 Feb 16.

PMID:
21324435
20.

D2-40/p63 defined lymph vessel invasion has additional prognostic value in highly proliferating operable node negative breast cancer patients.

Gudlaugsson E, Skaland I, Undersrud E, Janssen EA, Søiland H, Baak JP.

Mod Pathol. 2011 Apr;24(4):502-11. doi: 10.1038/modpathol.2010.199. Epub 2011 Feb 11.

21.

Biologic profiling of lymph node negative breast cancers by means of microRNA expression.

Janssen EA, Slewa A, Gudlaugsson E, Jonsdottir K, Skaland I, Søiland H, Baak JP.

Mod Pathol. 2010 Dec;23(12):1567-76. doi: 10.1038/modpathol.2010.177. Epub 2010 Sep 3.

22.

Local immune response in the microenvironment of CIN2-3 with and without spontaneous regression.

Øvestad IT, Gudlaugsson E, Skaland I, Malpica A, Kruse AJ, Janssen EA, Baak JP.

Mod Pathol. 2010 Sep;23(9):1231-40. doi: 10.1038/modpathol.2010.109. Epub 2010 May 28.

23.

LOH at 1p31 (ARHI) and proliferation in lymph node-negative breast cancer.

Janssen EA, Øvestad IT, Skaland I, Søiland H, Gudlaugsson E, Kjellevold KH, Nysted A, Søreide JA, Baak JP.

Cell Oncol. 2009;31(5):335-43. doi: 10.3233/CLO-2009-0479.

24.

Evaluation of 5 different labeled polymer immunohistochemical detection systems.

Skaland I, Nordhus M, Gudlaugsson E, Klos J, Kjellevold KH, Janssen EA, Baak JP.

Appl Immunohistochem Mol Morphol. 2010 Jan;18(1):90-6. doi: 10.1097/PAI.0b013e3181b0eaad.

PMID:
19661787
25.
26.

Prospective multicenter comparison of proliferation and other prognostic factors in lymph node negative lobular invasive breast cancer.

Gudlaugsson E, Skaland I, Janssen EA, van Diest PJ, Voorhorst FJ, Kjellevold K, zur Hausen A, Baak JP.

Breast Cancer Res Treat. 2010 May;121(1):35-40. doi: 10.1007/s10549-009-0442-x. Epub 2009 Jul 1.

PMID:
19568929
27.

Co-expression of estrogen receptor alpha and Apolipoprotein D in node positive operable breast cancer--possible relevance for survival and effects of adjuvant tamoxifen in postmenopausal patients.

Søiland H, Skaland I, Varhaug JE, Kørner H, Janssen EA, Gudlaugsson E, Baak JP, Søreide JA.

Acta Oncol. 2009;48(4):514-21. doi: 10.1080/02841860802620613.

PMID:
19107621
28.

The prognostic value of molecular biomarkers in tissue removed by curettage from FIGO stage 1 and 2 endometrioid type endometrial cancer.

Steinbakk A, Skaland I, Gudlaugsson E, Janssen EA, Kjellevold KH, Klos J, Løvslett K, Fiane B, Baak JP.

Am J Obstet Gynecol. 2009 Jan;200(1):78.e1-8. doi: 10.1016/j.ajog.2008.07.020. Epub 2008 Oct 30.

PMID:
18976730
29.

Prognostic relevance of androgen receptor detection in operable breast cancer.

Søiland H, Kørner H, Skaland I, Janssen EA, Gudlaugsson E, Varhaug JE, Baak JP, Søreide JA.

J Surg Oncol. 2008 Dec 1;98(7):551-8. doi: 10.1002/jso.21156.

PMID:
18937259
30.

Proliferation is the strongest prognosticator in node-negative breast cancer: significance, error sources, alternatives and comparison with molecular prognostic markers.

Baak JP, Gudlaugsson E, Skaland I, Guo LH, Klos J, Lende TH, Søiland H, Janssen EA, Zur Hausen A.

Breast Cancer Res Treat. 2009 May;115(2):241-54. doi: 10.1007/s10549-008-0126-y. Epub 2008 Jul 30. Review.

PMID:
18665447
31.

Adenomyoepitheliomatous lesions of the mammary glands in transgenic mice with targeted PLAG1 overexpression.

Declercq J, Skaland I, Van Dyck F, Janssen EA, Baak JP, Drijkoningen M, Van de Ven WJ.

Int J Cancer. 2008 Oct 1;123(7):1593-600. doi: 10.1002/ijc.23586.

32.

Androgen receptor determination in breast cancer: a comparison of the dextran-coated charcoal method and quantitative immunohistochemical analysis.

Søiland H, Skaland I, van Diermen B, Janssen EA, Körner H, Varhaug JE, Søreide JA, Baak JP.

Appl Immunohistochem Mol Morphol. 2008 Jul;16(4):362-70. doi: 10.1097/PAI.0b013e31815b9c92.

PMID:
18528280
33.

Comparison of apolipoprotein D determination methods in breast cancer.

Søiland H, Skaland I, Janssen EA, Gudlaugsson E, Körner H, Varhaug JE, Søreide JA, Baak JP.

Anticancer Res. 2008 Mar-Apr;28(2B):1151-60.

34.

Validating the prognostic value of proliferation measured by Phosphohistone H3 (PPH3) in invasive lymph node-negative breast cancer patients less than 71 years of age.

Skaland I, Janssen EA, Gudlaugsson E, Klos J, Kjellevold KH, Søiland H, Baak JP.

Breast Cancer Res Treat. 2009 Mar;114(1):39-45. doi: 10.1007/s10549-008-9980-x. Epub 2008 Mar 29.

PMID:
18373192
35.

Apolipoprotein D predicts adverse outcome in women >or=70 years with operable breast cancer.

Søiland H, Janssen EA, Kørner H, Varhaug JE, Skaland I, Gudlaugsson E, Baak JP, Søreide JA.

Breast Cancer Res Treat. 2009 Feb;113(3):519-28. doi: 10.1007/s10549-008-9955-y. Epub 2008 Mar 11.

PMID:
18330697
36.

Prognostic differences of World Health Organization-assessed mitotic activity index and mitotic impression by quick scanning in invasive ductal breast cancer patients younger than 55 years.

Skaland I, van Diest PJ, Janssen EA, Gudlaugsson E, Baak JP.

Hum Pathol. 2008 Apr;39(4):584-90. doi: 10.1016/j.humpath.2007.08.016. Epub 2008 Mar 4.

PMID:
18291440
37.

Low p53 and retinoblastoma protein expression in cervical intraepithelial neoplasia grade 3 lesions is associated with coexistent adenocarcinoma in situ.

Kruse AJ, Skaland I, Munk AC, Janssen E, Gudlaugsson E, Baak JP.

Hum Pathol. 2008 Apr;39(4):573-8. doi: 10.1016/j.humpath.2007.08.014. Epub 2008 Jan 30.

PMID:
18234283
38.

Digital image analysis improves the quality of subjective HER-2 expression scoring in breast cancer.

Skaland I, Ovestad I, Janssen EA, Klos J, Kjellevold KH, Helliesen T, Baak JP.

Appl Immunohistochem Mol Morphol. 2008 Mar;16(2):185-90. doi: 10.1097/PAI.0b013e318059c20c.

PMID:
18227722
39.

Metachronous cancer development in patients with sporadic colorectal adenomas-multivariate risk model with independent and combined value of hTERT and survivin.

Søreide K, Gudlaugsson E, Skaland I, Janssen EA, Van Diermen B, Körner H, Baak JP.

Int J Colorectal Dis. 2008 Apr;23(4):389-400. doi: 10.1007/s00384-007-0424-6.

PMID:
18189140
40.

Cervical intraepithelial neoplasia grade 3 lesions can regress.

Munk AC, Kruse AJ, van Diermen B, Janssen EA, Skaland I, Gudlaugsson E, Nilsen ST, Baak JP.

APMIS. 2007 Dec;115(12):1409-14. doi: 10.1111/j.1600-0463.2007.00769.x.

PMID:
18184413
41.

Phosphohistone H3 expression has much stronger prognostic value than classical prognosticators in invasive lymph node-negative breast cancer patients less than 55 years of age.

Skaland I, Janssen EA, Gudlaugsson E, Klos J, Kjellevold KH, Søiland H, Baak JP.

Mod Pathol. 2007 Dec;20(12):1307-15. Epub 2007 Oct 5.

43.

Comparing the prognostic value of PTEN and Akt expression with the Mitotic Activity Index in adjuvant chemotherapy-treated node-negative breast cancer patients aged <55 years.

Janssen EA, Søiland H, Skaland I, Gudlaugson E, Kjellevold KH, Nysted A, Søreide JA, Baak JP.

Cell Oncol. 2007;29(1):25-35.

44.

Comparing subjective and digital image analysis HER2/neu expression scores with conventional and modified FISH scores in breast cancer.

Skaland I, Øvestad I, Janssen EA, Klos J, Kjellevold KH, Helliesen T, Baak JP.

J Clin Pathol. 2008 Jan;61(1):68-71. Epub 2007 Apr 5.

45.

Dynamic behavioural interpretation of cervical intraepithelial neoplasia with molecular biomarkers.

Baak JP, Kruse AJ, Robboy SJ, Janssen EA, van Diermen B, Skaland I.

J Clin Pathol. 2006 Oct;59(10):1017-28. Epub 2006 May 5. Review.

46.

Combined p53 and retinoblastoma protein detection identifies persistent and regressive cervical high-grade squamous intraepithelial lesions.

Baak JP, Kruse AJ, Garland SM, Skaland I, Janssen EA, Tabrizi S, Fagerheim S, Robboy S, Nilsen ST.

Am J Surg Pathol. 2005 Aug;29(8):1062-6.

PMID:
16006801
47.

Lack of PTEN expression in endometrial intraepithelial neoplasia is correlated with cancer progression.

Baak JP, Van Diermen B, Steinbakk A, Janssen E, Skaland I, Mutter GL, Fiane B, Løvslett K.

Hum Pathol. 2005 May;36(5):555-61.

PMID:
15948123
48.

Quantitative molecular parameters to identify low-risk and high-risk early CIN lesions: role of markers of proliferative activity and differentiation and Rb availability.

Kruse AJ, Skaland I, Janssen EA, Buhr-Wildhagen S, Klos J, Arends MJ, Baak JP.

Int J Gynecol Pathol. 2004 Apr;23(2):100-9.

PMID:
15084837

Supplemental Content

Loading ...
Support Center